Molecular and clinical characterization of Colombian patients suffering from type III glycogen storage disease

Carolina Mantilla, Mónica Toro, María Elsy Sepúlveda, Margarita Insuasty, Diana di Filippo, Juan Álvaro López, Carolina Baquero, María Cristina Navas, Andrés Augusto Arias, .

Keywords: Glycogen storage disease type III/diagnosis, glycogen, glycogen debranching enzyme system, glycogenolysis

Abstract

Introduction: Type III glycogen storage disease (GSD III) is an autosomal recessive disorder in which a mutation in the AGL gene causes deficiency of the glycogen debranching enzyme. The disease is characterized by fasting hypoglycemia, hepatomegaly and progressive myopathy. Molecular analyses of AGL have indicated heterogeneity depending on ethnic groups. The full spectrum of AGL mutations in Colombia remains unclear.
Objective: To describe the clinical and molecular characteristics of ten Colombian patients diagnosed with GSD III.
Materials and methods: We recruited ten Colombian children with a clinical and biochemical diagnosis of GSD III to undergo genetic testing. The full coding exons and the relevant exon-intron boundaries of the AGL underwent Sanger sequencing to identify mutation.
Results: All patients had the classic phenotype of the GSD III. Genetic analysis revealed a mutation p.Arg910X in two patients. One patient had the mutation p.Glu1072AspfsX36, and one case showed a compound heterozygosity with p.Arg910X and p.Glu1072AspfsX36 mutations. We also detected the deletion of AGL gene 3, 4, 5, and 6 exons in three patients. The in silico studies predicted that these defects are pathogenic. No mutations were detected in the amplified regions in three patients.
Conclusion: We found mutations and deletions that explain the clinical phenotype of GSD III patients. This is the first report with a description of the clinical phenotype and the spectrum of AGL mutations in Colombian patients. This is important to provide appropriate prognosis and genetic counseling to the patient and their relatives.

 

Downloads

Download data is not yet available.
  • Carolina Mantilla Grupo de Gastrohepatología, Facultad de Medicina, Universidad de Antioquia, Medellín, Colombia
  • Mónica Toro Grupo de Gastrohepatología, Facultad de Medicina, Universidad de Antioquia, Medellín, Colombia
  • María Elsy Sepúlveda Grupo de Gastrohepatología, Facultad de Medicina, Universidad de Antioquia, Medellín, Colombia Hospital Pablo Tobón Uribe, Medellín, Colombia
  • Margarita Insuasty Grupo de Gastrohepatología, Facultad de Medicina, Universidad de Antioquia, Medellín, Colombia
  • Diana di Filippo Grupo de Gastrohepatología, Facultad de Medicina, Universidad de Antioquia, Medellín, Colombia
  • Juan Álvaro López Grupo de Inmunodeficiencias Primarias, Universidad de Antioquia, Medellín, Colombia Escuela de Microbiología, Universidad de Antioquia, Medellín, Colombia
  • Carolina Baquero Hospital Pablo Tobón Uribe, Medellín, Colombia
  • María Cristina Navas Grupo de Gastrohepatología, Facultad de Medicina, Universidad de Antioquia, Medellín, Colombia
  • Andrés Augusto Arias Grupo de Gastrohepatología, Facultad de Medicina, Universidad de Antioquia, Medellín, Colombia Grupo de Inmunodeficiencias Primarias, Universidad de Antioquia, Medellín, Colombia Escuela de Microbiología, Universidad de Antioquia, Medellín, Colombia

References

Wolfsdorf JI, Weinstein DA. Glycogen storage diseases. Rev Endocr Metab Disord. 2003;4:95-102.

Shin YS. Glycogen storage disease: Clinical, biochemical, and molecular heterogeneity. Semin Pediatr Neurol. 2006;13:115-20. https://doi.org/10.1016/j.spen.2006.06.007

Ozen H. Glycogen storage diseases: New perspectives. World J Gastroenterol. 2007;13:2541-53. https://doi.org/10.3748/wjg.v13.i18.2541

Cheng A, Zhang M, Okubo M, Omichi K, Saltiel AR. Distinct mutations in the glycogen debranching enzyme found in glycogen storage disease type III lead to impairment in diverse cellular functions. Hum Mol Genet. 2009;18:2045-52. https://doi.org/10.1093/hmg/ddp128

Endo Y, Fateen E, Aoyama Y, Horinishi A, Ebara T, Murase T, et al. Molecular characterization of Egyptian patients with glycogen storage disease type IIIa. J Hum Genet. 2005;50:538-42. https://doi.org/10.1007/s10038-005-0291-3

Shen JJ, Chen YT. Molecular characterization of glycogen storage disease type III. Curr Mol Med. 2002;2:167-75. https://doi.org/10.2174/1566524024605752

Haagsma EB, Smit GP, Niezen-Koning KE, Gouw AS, Meerman L, Slooff MJ. Type IIIb glycogen storage disease associated with end-stage cirrhosis and hepatocellular carcinoma. The Liver Transplant Group. Hepatology. 1997;25:537-40. https://doi.org/10.1002/hep.510250307

Sentner CP, Hoogeveen IJ, Weinstein DA, Santer R, Murphy E, McKiernan PJ, et al. Glycogen storage disease type III: Diagnosis, genotype, management, clinical course and outcome. J Inherit Metab Dis. 2016;39:697-704. https://doi.org/10.1007/s10545-016-9932-2

Rousseau-Nepton I, Okubo M, Grabs R, Consortium FC, Mitchell J, Polychronakos C, et al. A founder AGL mutation causing glycogen storage disease type IIIa in Inuit identified through whole-exome sequencing: A case series. CMAJ. 2015;187:E68-73. https://doi.org/10.1503/cmaj.140840

Mili A, Ben Charfeddine I, Mamai O, Abdelhak S, Adala L, Amara A, et al. Molecular and biochemical characterization of Tunisian patients with glycogen storage disease type III. J Hum Genet. 2012;57:170-5. https://doi.org/10.1038/jhg.2011.122

Parvari R, Moses S, Shen J, Hershkovitz E, Lerner A, Chen YT. A single-base deletion in the 3’-coding region of glycogen-debranching enzyme is prevalent in glycogen storage disease type IIIA in a population of North African Jewish patients. Eur J Hum Genet. 1997;5:266-70.

Santer R, Kinner M, Steuerwald U, Kjaergaard S, Skovby F, Simonsen H, et al. Molecular genetic basis and prevalence of glycogen storage disease type IIIA in the Faroe Islands. Eur J Hum Genet. 2001;9:388-91. https://doi.org/10.1038/sj.ejhg.5200632

Talente GM, Coleman RA, Alter C, Baker L, Brown BI, Cannon RA, et al. Glycogen storage disease in adults. Ann Intern Med. 1994;120:218-26.

Lucchiari S, Santoro D, Pagliarani S, Comi GP. Clinical, biochemical and genetic features of glycogen debranching enzyme deficiency. Acta Myol. 2007;26:72-4.

van Hoof F, Hers HG. The subgroups of type 3 glycogenosis. Eur J Biochem. 1967;2:265-70. https://doi.org/10.1111/j.1432-1033.1967.tb00134.x

Ding JH, de Barsy T, Brown BI, Coleman RA, Chen YT. Immunoblot analyses of glycogen debranching enzyme in different subtypes of glycogen storage disease type III. J Pediatr. 1990;116:95-100.

Yang-Feng TL, Zheng K, Yu J, Yang BZ, Chen YT, Kao FT. Assignment of the human glycogen debrancher gene to chromosome 1p21. Genomics. 1992;13:931-4. https://doi.org/10.1016/0888-7543(92)90003-B

Yang BZ, Ding JH, Enghild JJ, Bao Y, Chen YT. Molecular cloning and nucleotide sequence of cDNA encoding human muscle glycogen debranching enzyme. J Biol Chem. 1992;267:9294-9.

Bao Y, Yang BZ, Dawson TL Jr, Chen YT. Isolation and nucleotide sequence of human liver glycogen debranching enzyme mRNA: Identification of multiple tissue-specific isoforms. Gene. 1997;197:389-98. https://doi.org/10.1016/S0378-1119(97)00291-6

Lucchiari S, Fogh I, Prelle A, Parini R, Bresolin N, Melis D, et al. Clinical and genetic variability of glycogen storage disease type IIIa: Seven novel AGL gene mutations in the Mediterranean area. Am J Med Genet. 2002;109:183-90. https://doi.org/10.1002/ajmg.10347

Horinishi A, Okubo M, Tang NL, Hui J, To KF, Mabuchi T, et al. Mutational and haplotype analysis of AGL in patients with glycogen storage disease type III. J Hum Genet. 2002;47:55-9. https://doi.org/10.1007/s100380200000

Okubo M, Horinishi A, Suzuki Y, Murase T, Hayasaka K. Compound heterozygous patient with glycogen storage disease type III: Identification of two novel AGL mutations, a donor splice site mutation of Chinese origin and a 1-bp deletion of Japanese origin. Am J Med Genet. 2000;93:211-4. https://doi.org/10.1016/S0378-1119(97)00291-6

Okubo M, Horinishi A, Takeuchi M, Suzuki Y, Sakura N, Hasegawa Y, et al. Heterogeneous mutations in the glycogen-debranching enzyme gene are responsible for glycogen storage disease type IIIa in Japan. Hum Genet. 2000;106:108-15.

Ogimoto A, Okubo M, Okayama H, Shin YS, Endo Y, Ebara T, et al. A Japanese patient with cardiomyopathy caused by a novel mutation R285X in the AGL gene. Circ J. 2007;71:1653-6. https://doi.org/10.1253/circj.71.1653

Endo Y, Fateen E, El Shabrawy M, Aoyama Y, Ebara T, Murase T, et al. Egyptian glycogen storage disease type III - identification of six novel AGL mutations, including a large 1.5 kb deletion and a missense mutation p.L620P with subtype IIId. Clin Chem Lab Med. 2009;47:1233-8. https://doi.org/10.1515/CCLM.2009.281

Goldstein JL, Austin SL, Boyette K, Kanaly A, Veerapandiyan A, Rehder C, et al. Molecular analysis of the AGL gene: Identification of 25 novel mutations and evidence of genetic heterogeneity in patients with glycogen storage disease type III. Genet Med. 2010;12:424-30. https://doi.org/10.1097/GIM.0b013e3181d94eaa

Aoyama Y, Ozer I, Demirkol M, Ebara T, Murase T, Podskarbi T, et al. Molecular features of 23 patients with glycogen storage disease type III in Turkey: A novel mutation p.R1147G associated with isolated glucosidase deficiency, along with 9 AGL mutations. J Hum Genet. 2009;54:681-6. https://doi.org/10.1038/jhg.2009.100

Sentner CP, Vos YJ, Niezen-Koning KN, Mol B, Smit GP. Mutation analysis in glycogen storage disease type III patients in the Netherlands: Novel genotype-phenotype relationships and five novel mutations in the AGL gene. JIMD Rep. 2013;7:19-26. https://doi.org/10.1007/8904_2012_134

Zimmermann A, Rossmann H, Bucerzan S, Grigorescu-Sido P. A novel nonsense mutation of the AGL gene in a Romanian patient with glycogen storage disease type IIIa. Case Rep Genet. 2016;2016:8154910. https://doi.org/10.1155/2016/8154910

Rhouma FB, Messai H, Hsouna S, Halim NB, Cherif W, Fadhel SB, et al. History of settlement of villages from Central Tunisia by studying families sharing a common founder glycogenosis type III mutation. Mitochondrial DNA A DNA MappSeq Anal. 2016;27:3194-8. https://doi.org/10.3109/19401736.2015.1007331

Lu C, Qiu Z, Sun M, Wang W, Wei M, Zhang X. Spectrum of AGL mutations in Chinese patients with glycogen storage disease type III: Identification of 31 novel mutations. J Hum Genet. 2016;61:641-5. https://doi.org/10.1038/jhg.2016.24

Kumar P, Henikoff S, Ng PC. Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm. Nat Protoc. 2009;4:1073-81. https://doi.org/10.1038/nprot.2009.86

Adzhubei I, Jordan DM, Sunyaev SR. Predicting functional effect of human missense mutations using PolyPhen-2. Curr Protoc Hum Genet. 2013;7:20. https://doi.org/10.1002/0471142905.hg0720s76

Kircher M, Witten DM, Jain P, O’Roak BJ, Cooper GM, Shendure J. A general framework for estimating the relative pathogenicity of human genetic variants. Nat Genet. 2014;46:310-5. https://doi.org/10.1038/ng.2892

den Dunnen JT, Dalgleish R, Maglott DR, Hart RK, Greenblatt MS, McGowan-Jordan J, et al. HGVS Recommendations for the description of sequence variants: 2016 update. Hum Mutat. 2016;37:564-9. https://doi.org/10.1002/humu.22981

den Dunnen JT. Sequence variant descriptions: HGVS nomenclature and mutalyzer. Curr Protoc Hum Genet. 2016;90:7.13.1-7.13.19. https://doi.org/10.1002/cphg.2

Aradhya S, Lewis R, Bonaga T, Nwokekeh N, Stafford A, Boggs B, et al. Exon-level array CGH in a large clinical cohort demonstrates increased sensitivity of diagnostic testing for Mendelian disorders. Genet Med. 2012;14:594-603. https://doi.org/10.1038/gim.2011.65

Retterer K, Scuffins J, Schmidt D, Lewis R, Pineda Álvarez D, Stafford A, et al. Assessing copy number from exome sequencing and exome array CGH based on CNV spectrum in a large clinical cohort. Genet Med. 2015;17:623-9. https://doi.org/10.1038/gim.2014.160

Dagli A, Sentner CP, Weinstein DA. Glycogen storage disease type III. In: Pagon RA, Adam MP, Ardinger HH, Wallace SE, Amemiya A, Bean LJ, et al., editors. Gene Reviews. Washington, D.C.: University of Washington; 1993.

Kishnani PS, Austin SL, Arn P, Bali DS, Boney A, Case LE, et al. Glycogen storage disease type III diagnosis and management guidelines. Genet Med. 2010;12:446-63.

https://doi.org/10.1097/GIM.0b013e3181e655b6

Coleman RA, Winter HS, Wolf B, Gilchrist JM, Chen YT. Glycogen storage disease type III (glycogen debranching enzyme deficiency): Correlation of biochemical defects with myopathy and cardiomyopathy. Ann Intern Med. 1992;116:896-900. https://doi.org/10.7326/0003-4819-116-11-896

Maire I, Baussan C, Moatti N, Mathieu M, Lemonnier A. Biochemical diagnosis of hepatic glycogen storage diseases: 20 years French experience. Clin Biochem. 1991;24:169-78. https://doi.org/10.1016/0009-9120(91)90511-C

Lucchiari S, Pagliarani S, Salani S, Filocamo M, Di Rocco M, Melis D, et al. Hepatic and neuromuscular forms of glycogenosis type III: Nine mutations in AGL. Hum Mutat. 2006;27:600-1. https://doi.org/10.1002/humu.9426

Lucchiari S, Donati MA, Melis D, Filocamo M, Parini R, Bresolin N, et al. Mutational analysis of the AGL gene: Five novel mutations in GSD III patients. Hum Mutat. 2003;22:337. https://doi.org/10.1002/humu.9177

Zhang W, Cui H, Wong LJ. Application of next generation sequencing to molecular diagnosis of inherited diseases. Top Curr Chem. 2014;336:19-45. https://doi.org/10.1007/128_2012_325

Yubero D, Brandi N, Ormazabal A, García-Cazorla A, Pérez-Dueñas B, Campistol J, et al. Targeted next generation sequencing in patients with inborn errors of metabolism. PLoS One. 2016;11:e0156359. https://doi.org/10.1371/journal.pone.0156359

Silva AL, Romao L. The mammalian nonsense-mediated mRNA decay pathway: To decay or not to decay! Which players make the decision? FEBS Lett. 2009;583:499-505.

https://doi.org/10.1016/j.febslet.2008.12.058

Horinishi A, Murase T, Okubo M. Novel intronic polymorphisms (IVS6-73A/G and IVS21+124A/G) in the glycogen-debranching enzyme (AGL) gene. Hum Mutat. 2000;16:279. https://doi.org/10.1002/1098-1004(200009)16:

<279::AID-HUMU32>3.0.CO;2-X

Shamseldin HE, Al-Dosari M, Al-Jbali L, Rahbeeni Z, Qari A, Hashem M, et al. Study of consanguineous populations can improve the annotation of SNP databases. Eur J Med Genet. 2011;54:118-20. https://doi.org/10.1016/j.ejmg.2010.10.009

How to Cite
1.
Mantilla C, Toro M, Sepúlveda ME, Insuasty M, di Filippo D, López J Álvaro, et al. Molecular and clinical characterization of Colombian patients suffering from type III glycogen storage disease. biomedica [Internet]. 2018 May 1 [cited 2024 May 12];38(Sup.1):30-42. Available from: https://revistabiomedica.org/index.php/biomedica/article/view/3454
Published
2018-05-01

Altmetric

Article metrics
Abstract views
Galley vies
PDF Views
HTML views
Other views
QR Code